STN-Structure Search 1.5.05

10/754,171

=> d ibib abs 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:606472 CAPLUS
DOCUMENT NUMBER: 141:157141
TITLE: Preparation of diazepinoindolones as CHK-1 kinase inhibitors.
INVENTOR(S): Ninkovic, Sacha; Bennett, Michael John; Rui, Yuanjin; Wang, Fen; Benedict, Suzanne Pritchett; Teng, Min
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 279 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063198	A1	20040729	WO 2004-IB26	20040105

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ

PRIORITY APPLN. INFO.: US 2003-439396P P 20030109
OTHER SOURCE(S): MARPAT 141:157141
GI



I

AB Title compds. [I; X = O , S; A = CR1, N; YZ = OCH2, N:CH; R1 = alkyl, COR5; CONR6R7, R35, R36, (substituted) alkenyl, alkynyl; R2 = H, OH, alkyl, COR8; C:SR9, C:SNR10R11, R38, R39; R3 = alkyl, COR12, CONR13R14, NR15COR16, NR17SO2R18, etc.; R4 = H, F, Br, Cl, alkyl; R5 = H, alkyl, alkoxy, R36; R6, R7 = H, alkyl, R36; R8 = alkyl, alkenyl, alkynyl, NH2, R36, R37; R9, R10, R11, R17 = H, alkyl, R36; R13, R15 = H, alkyl; R14 = H, alkyl, CH2CO2alkyl, R36; R16 = H, alkyl, alkenyl, alkynyl, NH2, R36, R37; R18 = alkyl, R36; R36 = cycloalkyl, heterocyclyl, aryl, heteroaryl; R37 = NR25R26, R27O; R25 = H, alkyl; R26 = CO2CMe3, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R38 = R28SOn; n = 0-2; R39 = R29R30NSOn; R28, R30 = alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R29 = H, alkyl], were prepared as CHK-1 inhibitors (no data). Thus, 3-formyl-5-pyridin-3-yl-1H-indole-4-carboxylic acid Me ester (preparation given), N2H4, and HOAc were heated at 80° in MeOH for 24 h to give 23% 7-pyridin-3-yl-1,5-dihydro-[1,2]diazepino[4,5,6-cd]indol-6-one.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:428911 CAPLUS
DOCUMENT NUMBER: 137:6205
TITLE: Preparation of benzazepinones, isoquinolinones and related compounds as inhibitors of poly(ADP-ribose) polymerase (PARP) for the prevention and/or treatment of tissue damage from cell trauma or cell death due to necrosis or apoptosis.
INVENTOR(S): Ferraris, Dana V.; Li, Jia-He; Kalish, Vincent J.; Zhang, Jie
PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002044183	A2	20020606	WO 2001-US44815		20011130
WO 2002044183	A3	20030522			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002036521	A5	20020611	AU 2002-36521		20011130
US 2003022883	A1	20030130	US 2001-996776		20011130
EP 1339402	A2	20030903	EP 2001-986053		20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004517831	T2	20040617	JP 2002-546553		20011130
PRIORITY APPLN. INFO.:			US 2000-250132P	P	20001201
			US 2001-310274P	P	20010809
			WO 2001-US44815	W	20011130

OTHER SOURCE(S): MARPAT 137:6205
GI



I



II



III



IV

AB This invention discloses the preparation of title compds. I and II, their pharmaceutically acceptable salts, and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP) [wherein: A = N, C, CH2, CH; B = C, N, NH, S, SO, SO2; X = C, CH, N; Y = C, N; Z = C, CH2, N, CO; provided that at least one of X, Y, or Z is N; R1, R2, R3, R5 when present are optionally or independently = H, OH, :O, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, amine, COR8 (R8 = H, OH, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl), OR6, NR6R7 (R6, R7 independently = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl); R1, R2, R3, R5 optionally form ring through a straight or branched C1-4alkyl which may addnl. contain 1-2 double or triple bonds; R4 = 1-3 of H, halo, or alkyl; with proviso that when A, X, or Z = C, then R1, R2, R3 when present may also independently = halogen, CN, O; R9, R10, R11, R12 optionally or independently = H, halogen, amino, OH, halo-amine, O-alkyl, O-aryl, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, COR8; R13 = 1-3 of H, halogen, alkoxy, alkyl]. For example, cyclocondensation of formylindazole III (prepared from Me indole-4-carboxylate and NaNO2/AcOH), with hydrazine provided claimed benzoazulenone IV as a white solid. Benzoazulenone IV inhibited human recombinant PARP at an IC50 of 0.018 μM. PARP IC50 inhibition studies for an addnl. 156 examples are provided, ranging in values from 0.01 to 20 μM. Biol. data are provided for the in vivo treatment of focal cerebral ischemia and gout via PARP inhibition with selected compds. II. The present invention is believed to protect cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide through inhibition of PARP activity.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:493542 CAPLUS

DOCUMENT NUMBER: 133:105028

TITLE: Preparation of 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5(1H)-ones and analogs as poly(ADP-ribose) polymerase inhibitors

INVENTOR(S): Webber, Stephen Evan; Canan-Koch, Stacie S.; Tikhe, Jayashree; Thoresen, Lars Henrik

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA; Cancer Research

SOURCE:	Campaign Technology Limited PCT Int. Appl., 141 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042040	A1	20000720	WO 2000-US411	20000110
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2360003	AA	20000720	CA 2000-2360003	20000110
AU 2000024088	A5	20000801	AU 2000-24088	20000110
EP 1140936	A1	20011010	EP 2000-902358	20000110
EP 1140936	B1	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008614	A	20011016	BR 2000-8614	20000110
TR 200102005	T2	20011221	TR 2001-200102005	20000110
SI 20691	C	20020430	SI 2000-20013	20000110
EE 200100364	A	20021015	EE 2001-364	20000110
JP 2002534523	T2	20021015	JP 2000-593608	20000110
US 6495541	B1	20021217	US 2000-479896	20000110
NZ 512731	A	20040130	NZ 2000-512731	20000110
AT 261963	E	20040415	AT 2000-902358	20000110
PT 1140936	T	20040630	PT 2000-902358	20000110
ES 2218110	T3	20041116	ES 2000-902358	20000110
ZA 2001005399	A	20020701	ZA 2001-5399	20010629
NO 2001003313	A	20010910	NO 2001-3313	20010704
LV 12770	B	20020520	LV 2001-115	20010801
BG 105811	A	20020531	BG 2001-105811	20010810
LT 4936	B	20020725	LT 2001-83	20010810
HK 1040992	A1	20040910	HK 2002-102476	20020403
US 2003078254	A1	20030424	US 2002-264018	20021002

PRIORITY APPLN. INFO.:

US 1999-115431P	P	19990111
US 2000-479896	A1	20000110
WO 2000-US411	W	20000110

OTHER SOURCE(S): MARPAT 133:105028

GI



I

AB Title compds. [I; R1 = H, halo, alk(en)yl, (hetero)aryl, alkoxycarbonyl, etc.; R1,R3 = H or alkyl; R4 = H, halo, alkyl; X = O or S; Z = CR5R6(CR7R8)n or N:CR5; R5-R8 = H, alk(en)yl, (hetero)aryl, etc.; n = 0 or 1] were prepared Thus, Me indole-4-carboxylate was converted in 3 steps to Me 3-aminoindole-4-carboxylate which was cyclized and the product brominated to give I (R2-R4 = H, X = O, Z = CH2)(II; R1 = Br). The latter was condensed with PhB(OH)2 to give II (R1 = Ph). Data for biol. activity of I were given.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:121125 CAPLUS
DOCUMENT NUMBER: 88:121125
TITLE: 3,4-Bridged indoles: Part II. Synthesis of 6-keto-1,5-dihydro-4,5-diazepino[6,5,4-cd]indoles and 3,4-disubstituted indoles as 5-HT antagonists
AUTHOR(S): Ananthanarayanan, C. V.; Rastogi, Shri Nivas; Patnaik, G. K.; Anand, Nitya
CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1977), 15(8), 710-14
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 88:121125
GI



I



II

AB The diazepinoindoles I (R = H, Me) were prepared by formylation of II (R = H, Me; R1 = CO2Me; R2 = H) to give II (R2 = CHO), which were cyclized with H2NNH2.H2O. Several indole derivs., e.g. I (R = H, R1 = CH2NHAc, R2 = CHO; R = H, R1 = CN, CO2Me, R2 = CH2NHCMe3) were prepared from I (R = R2 = H, R1 = CN). Substitution of indole N lowers the anti-5-HT activity. The most potent and specific anti-5-HT compound of this series, I, is very weak as compared to cyproheptadiene, a standard anti-5-HT drug.

=> d his

(FILE 'HOME' ENTERED AT 13:13:17 ON 05 JAN 2005)

FILE 'REGISTRY' ENTERED AT 13:13:30 ON 05 JAN 2005
L1 STRUCTURE UPLOADED
L2 29 S L1
L3 429 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:14:44 ON 05 JAN 2005

L4 4 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N
G2 C,N
G3 O,S

Structure attributes must be viewed using STN Express query preparation.

=>

PALM INTRANET

Day : Wednesday
Date: 1/5/2005
Time: 12:51:49

Inventor Name Search Result

Your Search was:

Last Name = BENEDICT
First Name = SUZANNE

Application#	Patent#	Status	Date Filed	Title	Inventor Name 4
60439396	Not Issued	159	01/09/2003	TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY	BENEDICT, SUZANNE
10754171	Not Issued	030	01/09/2004	TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY	BENEDICT, SUZANNE
09783584	6620828	150	02/15/2001	THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES AND METHODS FOR THEIR USE	BENEDICT, SUZANNE PRITCHETT
09587530	Not Issued	164	06/02/2000	THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES AND METHOD FOR THEIR USE	BENEDICT, SUZANNE PRITCHETT

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Benedict **First Name** Suzanne

Search